Navamedic ASA Celebrates First Approval of Innovative Medical Device OraFID® for Pharmaceuticals

Navamedic ASA Receives Landmark Approval for OraFID®



Navamedic ASA, a prominent Nordic pharmaceutical company, has achieved a significant milestone with the recent approval of its innovative medical device, OraFID®, by the Swedish Medical Products Agency. This approval marks the first time that OraFID® has been recognized as a primary package for a pharmaceutical product across Europe, setting the stage for a new era in medication delivery.

Kathrine Gamborg Andreassen, the Chief Executive Officer of Navamedic, expressed her enthusiasm about this development, stating, "OraFID® is a unique, fully mechanical medical device that dispenses precise quantities of minitablets to patients. It enables personalized, fine-tuned treatment with minitablets, and I am thrilled to see the approval of this important milestone."

The Functionality of OraFID®


OraFID® is tailored for treatments that require a narrow therapeutic window and allows for the hyper-fractionation of doses to enhance patient care. By allowing patients to take minitablets, each capsule can deliver a specific fraction of the required dose, ultimately supporting personalized healthcare solutions. The device allows users to dispense an exact number of minitablets with just a few twists of the device, facilitating both accuracy and ease of use in medication administration.

Approved Integration with Flexilev®


This groundbreaking device has been approved as part of an integral combination product for Flexilev®, Navamedic’s medication designed for the treatment of Parkinson's disease. This collaboration not only underscores the efficacy of OraFID® but also emphasizes Navamedic's commitment to improving the quality of life for patients managing chronic conditions like Parkinson's, where precise medication delivery can greatly enhance treatment outcomes.

Market Launch Date


With the approval now in hand, the launch of the OraFID® device in Nordic markets is anticipated in October 2025. This proactive approach aims to provide immediate access to patients and healthcare providers, equipping them with the necessary tools to manage complex medication regimens more effectively.

About Navamedic ASA


Navamedic ASA is headquartered in Oslo, Norway, and has been actively listed on the Oslo Stock Exchange since 2006 under the ticker symbol NAVA. The company is devoted to enhancing quality of life through the provision of a wide array of high-quality prescription and consumer health products to hospitals and pharmacies across the Nordic and Benelux regions. Navamedic’s growing portfolio addresses major public health concerns, including obesity, Parkinson's disease, and gastrointestinal disorders, showcasing their commitment to empowering individuals to lead healthier lives.

As Navamedic continues to expand its footprint, the company prides itself on understanding the specific healthcare needs of each country it operates in, allowing it to strategically cater to the demands of diverse markets. This local insight, coupled with a committed approach to innovation, positions Navamedic as a preferred partner for international companies seeking to enter Nordic markets and emphasizes their vital role in the global healthcare ecosystem.

Looking Ahead


With the advent of the OraFID® device, patients and healthcare providers alike can look forward to a new standard in medication management, highlighting Navamedic's dedication to using technology to improve patient outcomes. As the October launch date approaches, all eyes will be on Navamedic as they prepare to transform the way medications are dispensed and consumed across the regions they serve.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.